Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.
Wick W, et al. Among authors: hopkins k.
Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. doi: 10.1158/1078-0432.CCR-15-3153. Epub 2016 May 3.
Clin Cancer Res. 2016.
PMID: 27143690
Free article.
Clinical Trial.